MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)*
Organization & Developments: Arcturus Therapeutics
Parents
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)*
Children
*Late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.
2019: Assessing Arcturus Therapeutics_seekingalpha.com
2020: Arcturus: Flying Due To COVID-19, But Looking Like A Risky Bet
2020: Why Arcturus Therapeutics Stock Crumbled On Its Covid Vaccine Update
2021: Arcturus: Developing A Covid-19 Vaccine But Too Little, Too Late
2022: Arcturus touts $63M BARDA award for new mRNA influenza vaccine, hoping to prep against future pandemics
2023: Arcturus: COVID Vaccine Approval Shots In Japan And Europe Key To Unlocking Upside_ seekingalpha.com
2024: Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA
2024: Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future
2024: Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
2024: Arcturus: H1 2024 Rare Disease Drug Data On Deck
2024: Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
2024: Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
2025: Arcturus: Downgrading As mRNA Promise Meets Market Reality
Jumps
Finance & Acquisitions: Arcturus Therapeutics
Key People: Arcturus Therapeutics